FrancophonIA/ELRC3.0 huggingface dataset:
English: The duration of therapy was 48 weeks with a follow-up period of 6 months except for patients infected with genotypes 2 or 3 and viral load < 800,000 IU/mL (Amplicor) who were treated for 24 weeks with a 6 month follow-up period.
Maltese: It-tul tat-terapija kien 48 ġimgħa b'perijodu ta' follow up ta' 6 xhur ħlief għal pazjenti infettati b'ġenotipi 2 jew 3 u viral load < 800,000 IU/mL (Amplicor) li kienu trattati għal 24 ġimgħa b'perijodu ta' follow up ta' 6 xhur.
English: Ribavirin Teva Pharma B.V. 400 mg film-coated tablets ribavirin
Maltese: Ribavirin Teva Pharma B.V. 400 mg pilloli miksija b'rita ribavirin
English: Reports of mitochondrial toxicity, in particular lactic acidosis and pancreatitis, of which some fatal, have been reported (see section 4.4).
Maltese: Rapporti ta' tossiċità mitokondrijali, l-aktar aċidożi lattika u pankreatite, li minnhom ftit kienu letali, kienu rapportati (ara sezzjoni 4.4).
English: Ulcerative stomatitis, stomatitis, mouth ulceration, colitis, upper right quadrant pain, dyspepsia, gastroesophageal reflux*, glossitis, cheilitis, abdominal distension, gingival bleeding, gingivitis, loose stools, tooth disorder, constipation, flatulence
Maltese: Stomatite ulċerattiva, stomatite, postumetti, kolite, uġigħ filkwadrant lemini ta' fuq, dispepsja, rifluss gastroesofageali*, glossite, ċeilite, distensjoni addominali, ħanek bid-demm, ġinġivite, ippurgar maħlul, disturbi tas-snien, stitikezza, gass
English: Eligible patients for these trials had chronic hepatitis C confirmed by a positive HCV-RNA polymerase chain reaction assay (PCR) (> 30 IU/mL), a liver biopsy consistent with a histological diagnosis of chronic hepatitis with no other cause for the chronic hepatitis, and abnormal serum ALT.
Maltese: Pazjenti eliġibbli għal dawn l-istudji kellhom epatite kronika Ċ ikkonfermata mill-assaġġ pożittiv permezz tal-polymerase chain reaction (PCR) (> 30 IU/mL) għal HCV-RNA, bijopsija talfwied konsistenti ma dijanjosi istoloġika ta' epatite kronika mingħajr l-ebda kawża oħra għall-epatite kronika u kwantitajiet anormali ta' ALT fis-serum.
English: Oral formulations of ribavirin monotherapy have been investigated as therapy for chronic hepatitis C in several clinical trials.
Maltese: Formulazzjonijiet orali tal-monoterapija ta' ribavirin kienu mistħarrġa bħala terapija għal epatite Ċ kronika f'diversi provi kliniċi.
English: Retreatment of relapse patients with Ribavirin and interferon alfa-2b combination treatment
Maltese: Trattament mill-ġdid ta' pazjenti li rkadew b'trattament kkombinat b'Ribavirin u interferon alfa-2b
English: Upon multiple dosing, ribavirin accumulates extensively in plasma with a six-fold ratio of multiple-dose to single-dose AUC12hr.
Maltese: Wara dożaġġ multiplu, ribavirin jakkumula b'mod estensiv fil-plażma bi proporzjon ta' sitt darbiet għal kull doża ta' AUC12hr.
English: Ribavirin Teva Pharma B.V. 200 mg film-coated tablets ribavirin
Maltese: Ribavirin Teva Pharma B.V. 200 mg pilloli miksija b'rita ribavirin
English: - Haemoglobinopathies (e.g., thalassemia, sickle-cell anaemia).
Maltese: - Emoglobinopatiji (eż., talassemija, anemija biċ-ċelluli forma ta' minġel).
English: No interaction studies have been conducted with ribavirin and other medicinal products, except for peginterferon alfa-2b, interferon alfa-2b and antacids.
Maltese: Ma saru l-ebda studji dwar l-interazzjoni bejn Ribavirin u prodotti mediċinali oħra, ħlief għal peginterferon alfa-2b, interferon alfa-2b u antaċidi.
English: Psoriasis, aggravated psoriasis, eczema, photosensitivity reaction, maculopapular rash, erythematous rash, night sweats, hyperhidrosis, dermatitis, acne, furuncule, erythema, urticaria, skin disorder, bruise, sweating increased, abnormal hair texture, nail disorder*
Maltese: Psorjasi, psorjasi aggravat, ekżema, reazzjoni ta' fotosensittività, raxx makulopapulari, raxx eritematsi, għaraq bil-lejl, iperidrosi, dermatite, akne, furunkulosi*, eritema, urtikarja, disturbi tal-ġilda, tbenġil, żieda fl-għaraq, tessut tax-xagħar mhux normali, disturbi fid-dwiefer*
English: Therefore, there is a minimal potential for P450 enzyme-based interactions.
Maltese: Għalhekk, hemm probabilità minima li jseħħu interazzjonijiet abbażi tal-enżima P450.
English: Three trials examined the use of interferon in naïve patients, two with ribavirin + interferon alfa-2b (C95-132 and I95-143) and one with ribavirin + peginterferon alfa-2b (C/I98-580).
Maltese: Tliet provi eżaminaw l-użu ta' ribavirin + interferon alfa-2b (C95-132 u I95-143).
English: Blood thyroid stimulating hormone increased, thyroglobulin increased
Maltese: Żieda fil-livell tal-ormon li jistimula t-tirojdi, żieda f'tiroglobulin
English: The mean AUCtf was threefold greater in subjects with creatinine clearance between 10 and 30 mL/min compared with control subjects.
Maltese: Il-medja tal-AUCtf kienet tliet darbiet aktar f'individwi bi tneħħija tal-kreatinina bejn 10 u 30 mL/min meta mqabbla mal-individwi bħala kontroll.
English: In a juvenile rat toxicity study, pups dosed from postnatal day 7 to 63 with 10, 25 and 50 mg/kg of ribavirin demonstrated a dose-related decrease in overall growth, which was subsequently manifested as slight decreases in body weight, crown-rump length and bone length.
Maltese: Fi studju dwar it-tossiċità fuq firien, frieħ li ngħataw doża ta' bejn 7 sa 63 jum wara t-twelid b'10, 25 u 50 mg/kg ta' ribavirin urew tnaqqis ġenerali fit-tkabbir skont id-doża, li wara deher bħala tnaqqis żgħir fil-piż tal-ġisem, it-tul tal-crown-rump (bejn ir-ras u l-patata) u t-tul tal-għadam.
English: Hepatomegaly, jaundice, hyperbilirubinemia*
Maltese: Epatomegalija, suffejra, iperbilirubinemija*
English: The incidence and severity of teratogenic effects increased with escalation of the dose.
Maltese: L-inċidenza u s-severità tal-effetti teratoġeniċi żdiedu maż-żieda fid-doża.
English: * For patients receiving a 1,000 mg (< 75 kg) or 1,200 mg (> 75 kg) dose, ribavirin dose should be reduced to 600 mg/day (administered as one 200 mg tablet in the morning and two 200 mg tablets in the evening).
Maltese: * Għal pazjenti li qed jirċievu doża ta' 1,000 mg (< 75 kg) jew 1,200 mg (> 75 kg), id-doża ta' ribavirin għandha titnaqqas għal 600 mg/jum (mogħtija bħala pillola waħda ta' 200 mg filgħodu u żewġ pilloli ta' 200 mg filgħaxija).
English: In 3- and 6-month studies in mice to investigate ribavirin-induced testicular and sperm effects, abnormalities in sperm, occurred at doses of 15 mg/kg and above.
Maltese: Fi studji ta' 3 u 6 xhur fuq il-ġrieden sabiex jiġu mistħarrġa l-effetti fuq it-testikuli u fuq l-isperma kkaġunati minn ribavirin, anormalitajiet fl-isperma seħħew f'dożi ta' 15 mg/kg u aktar.
English: Depression, anxiety, emotional lability, insomnia
Maltese: Dipressjoni, ansjetà, burdati emozzjonali, insomnja
English: Hepatic decompensation in HCV/HIV co-infected patients with advanced cirrhosis:
Maltese: Dikumpensazzjoni epatika f'pazjenti infettati b'HCV/HIV fl-istess ħin li jkollhom ċirrożi avanzata:
English: Standard haematologic tests, blood chemistries (complete blood count [CBC] and differential, platelet count, electrolytes, serum creatinine, liver function tests, uric acid) and pregnancy tests must be conducted in all patients prior to initiating therapy.
Maltese: Qabel ma tinbeda t-terapija il-pazjenti kollha għandhom isirulhom t-testijiet ematoloġiċi standard, testijiet tal-kimika tad-demm (għadd sħiħ u divrenzjali ta' ċelluli tad-demm [CBC - complete blood count], l-għadd ta' plejtlits, elettroliti, kreatinin fis-serum, testijiet tal-funzjoni tal-fwied, l-aċidu uriku) u testijiet tat-tqala.
English: Headache, dizziness
Maltese: Ipotajrojdiżmu, Ipertajrojdiżmu
English: Ribavirin dose (mg/kg)
Maltese: Piż tal-ġisem (kg)
English: Pregnancy
Maltese: Emolisi
English: An increase in uric acid and indirect bilirubin values associated with haemolysis was observed in some patients treated with Ribavirin Teva Pharma B.V. used in combination with peginterferon alfa-2b or interferon alfa-2b in clinical trials, but values returned to baseline levels by four weeks after the end of therapy.
Maltese: Żieda fl-aċidu uriku u fil-valuri indiretti ta' bilirubin assoċjati ma' emoliżi kienet osservata f'xi pazjenti trattati b'Ribavirin Teva Pharma B.V. flimkien ma' peginterferon alfa-2b jew interferon alfa-2b fi provi kliniċi, imma l-valuri marru lura għal dawk tal-livelli bażi ta' riferiment wara erba' ġimgħat minn meta ntemmet it-terapija.
English: Suicidal ideation, psychosis, aggressive behaviour, confusion, agitation, anger, mood altered, abnormal behaviour nervousness, sleep disorder, decreased libido, apathy, abnormal dreams, crying,
Maltese: Ħsibijiet suwiċidali, psikosi, mġieba aggressiva, konfużjoni, aġitazzjoni, rabja, tibdil fil-burdata, mġieba mhux normali, nervożità, tnaqqis fil-ħajra sesswali, apatija, disturbi fl-irqad, ħolm mhux normali, biki mhux normali,
English: Mouth ulceration, stomatitis ulcerative, stomatitis, aphthous stomatitis, dyspepsia, cheilosis, glossitis, gastroesophageal reflux, rectal disorder, gastrointestinal disorder, constipation, loose stools, toothache, tooth disorder, stomach discomfort, oral pain
Maltese: Ulċeri fil-ħalq, stomatite ulcerativa, stomatite, stomatite aftusa, dispepsja, ċejlosi, glossite, rifluss gastroesofageali, disturbi fir-rektum, disturbi gastrointestinali, stitikezza, ippurhar merħi, uġigħ fis-snien, disturbi fis-snien, dwejjaq fl-istonku, uġigħ fil-ħalq
English: Detailed information on this medicine is available on the website of the European Medicines Agency http://www.ema.europa.eu
Maltese: Informazzjoni dettaljata dwar dan il-prodott mediċinali tinsab fuq is-sit elettroniku tal-Aġenzija Ewropea għall-Mediċini http://www.ema.europa.eu/.
English: Diabetes mellitus, hypertriglyceridemia*
Maltese: Dijabete mellitus, ipertrigliċeridemija
English: EU/1/09/527/009 - 14 tablets EU/1/09/527/010 - 28 tablets EU/1/09/527/011 - 42 tablets EU/1/09/527/012 - 56 tablets EU/1/09/527/013 - 84 tablets EU/1/09/527/014 - 112 tablets EU/1/09/527/015 - 140 tablets EU/1/09/527/016 - 168 tablets
Maltese: EU/1/09/527/009 - 14-il pillola EU/1/09/527/010 - 28 pillola EU/1/09/527/011 - 42 pillola EU/1/09/527/012 - 56 pillola EU/1/09/527/013 - 84 pillola EU/1/09/527/014 - 112 pillola EU/1/09/527/015 - 140 pillola EU/1/09/527/016 - 168 pillola
English: If needed, 2nd dose reduction of Ribavirin Teva Pharma B.V. is by an additional 200 mg/day.
Maltese: Jekk ikun hemm bżonn, it-2ni tnaqqis fid-doża ta' Ribavirin Teva Pharma B.V. ikun b'200 mg/jum oħra.
English: In this trial, the combination of ribavirin and peginterferon alfa-2b (1.5 micrograms/kg/week) was significantly more effective than the combination of ribavirin and interferon alfa-2b, particularly in patients infected with Genotype 1.
Maltese: F'din il-prova, il-kombinazzjoni ta' ribavirin ma' peginterferon alfa-2b (1.5 mikrogrammi/kg/ġimgħa) kienet aktar effettiva b'mod sinifikanti mill-kombinazzjoni ta' ribavirin u interferon alfa-2b, b'mod partikolari f'pazjenti infettati bil-Ġenotip 1.
English: Patients were randomized to receive either ribavirin (800-1,200 mg/day based on weight) plus peginterferon alfa-2b (100 or 150 µg/week based on weight) or ribavirin (8001,200 mg/day based on weight) plus interferon alfa-2b (3 MIU TIW).
Maltese: Il-pazjenti ntgħażlu b'mod każwali biex jew jirċievu ribavirin (800-1,200 mg/jum skont il-piż) flimkien ma' peginterferon alfa-2b (100 jew 150 µg/ġimgħa skont il-piż) jew ribavirin (8001,200 mg/jum skont il-piż) flimkien ma' interferon alfa-2b (3 MIU TIW).
English: Only 1 subject discontinued therapy as the result of an adverse reaction (thrombocytopenia).
Maltese: Individwi 1 biss ma komplix it-terapija bħala riżultat ta' reazzjoni avversa tromboċitopenija).
English: EU/1/09/527/001 - 14 tablets EU/1/09/527/002 - 28 tablets EU/1/09/527/003 - 42 tablets EU/1/09/527/004 - 56 tablets EU/1/09/527/005 - 84 tablets EU/1/09/527/006 - 112 tablets EU/1/09/527/007 - 140 tablets EU/1/09/527/008 - 168 tablets
Maltese: EU/1/09/527/001 - 14-il pillola EU/1/09/527/002 - 28 pillola EU/1/09/527/003 - 42 pillola EU/1/09/527/004 - 56 pillola EU/1/09/527/005 - 84 pillola EU/1/09/527/006 - 112 pillola EU/1/09/527/007 - 140 pillola EU/1/09/527/008 - 168 pillola
English: For BMI, pre-treatment to end of long-term follow up, BMI for age percentiles decreased 1.8 and 7.5 percentiles among children treated for 24 weeks or 48 weeks, respectively.
Maltese: Għall-BMI, minn qabel il-kura sal-aħħar tas-segwitu fit-tul ta' 5 snin, il-perċentwali tal-BMI għall-età naqsu b'1.8 u 7.5 perċentwali fost tfal ikkurati għal 24 ġimgħa jew 48 ġimgħa, rispettivament.
English: Ribavirin Teva Pharma B.V. 200 mg film-coated tablets
Maltese: Ribavirin Teva Pharma B.V. 200 mg pilloli miksija b'rita
English: Amnesia, memory impairment, syncope, migraine, ataxia,, paraesthaesia, dysphonia, taste loss, hypoaesthesia, hyperaesthesia, hypertonia, somnolence, disturbance in attention, tremor, dysgeusia
Maltese: Amnesija, indeboliment fil-memorja, sinkope, emigranja, atassja, tregħid, parestesija, disfonja, telf fit-togħma, ipoestesija, iperestesija, ipertonja, ngħas, emigranja, disturbi fl-attenzjoni, rogħda, ipertonja, disgewsja
English: What Ribavirin Teva Pharma B.V. looks like and contents of the pack
Maltese: Kif jidher Ribavirin Teva Pharma B.V. u l-kontenut tal-pakkett
English:  2 g/dL decrease in haemoglobin during any 4 week period during treatment (permanent dose reduction)
Maltese: Tnaqqis ta'  2 g/dL fl-emoglobina matul kwalunkwe perjodu ta' 4 ġimgħat waqt it-trattament (tnaqqis permanenti fid-doża)
English: Table 1 Ribavirin Teva Pharma B.V. dose based on body weight when used in combination with interferon alfa-2b in paediatric patients
Maltese: Tabella 1 Doża ta' Ribavirin Teva Pharma B.V. bażata fuq il-piż tal-ġisem meta tintuża flimkien ma' interferon alfa-2b f'pazjenti pedjatriċi
English: EU/1/09/527/009 (14 tablets) EU/1/09/527/010 (28 tablets) EU/1/09/527/011 (42 tablets) EU/1/09/527/012 (56 tablets) EU/1/09/527/013 (84 tablets) EU/1/09/527/014 (112 tablets) EU/1/09/527/015 (140 tablets) EU/1/09/527/016 (168 tablets)
Maltese: EU/1/09/527/009 (14-il pillola) EU/1/09/527/010 (28 pillola) EU/1/09/527/011 (42 pillola) EU/1/09/527/012 (56 pillola) EU/1/09/527/013 (84 pillola) EU/1/09/527/014 (112 pillola) EU/1/09/527/015 (140 pillola) EU/1/09/527/016 (168 pillola)
English: EU/1/09/527/001 (14 tablets) EU/1/09/527/002 (28 tablets) EU/1/09/527/003 (42 tablets) EU/1/09/527/004 (56 tablets) EU/1/09/527/005 (84 tablets) EU/1/09/527/006 (112 tablets) EU/1/09/527/007 (140 tablets) EU/1/09/527/008 (168 tablets)
Maltese: EU/1/09/527/001 (14-il pillola) EU/1/09/527/002 (28 pillola) EU/1/09/527/003 (42 pillola) EU/1/09/527/004 (56 pillola) EU/1/09/527/005 (84 pillola) EU/1/09/527/006 (112 pillola) EU/1/09/527/007 (140 pillola) EU/1/09/527/008 (168 pillola)
English: • Ribavirin (1,000/1,200 mg/day) + interferon alfa-2b (3 MIU three times a week) (n = 505).
Maltese: • Ribavirin (1,000/1,200 mg/jum) + interferon alfa-2b (3 MIU tliet darbiet fil-ġimgħa)
English: Multiple-dose pharmacokinetic properties for ribavirin and interferon alfa-2b in children and adolescents with chronic hepatitis C between 5 and 16 years of age are summarized in Table 10.
Maltese: Il-karatteristiċi tal-farmakokinetiċi b'ħafna dożi għal ribavirin u interferon alfa-2b fi tfal u adoloxxenti b'epatite Ċ kronika ta' età bejn 5 u 16-il sena qed jintwerew fil-qosor f'Tabella 10.
English: Ribavirin Teva Pharma B.V. 400mg film-coated tablets
Maltese: Ribavirin Teva Pharma B.V. 400 mg pilloli miksija b'rita
English: • Men
Maltese: Teva
English: Patients were randomized to receive either ribavirin (800 mg/day) plus peginterferon alfa-2b (1.5 µg/kg/week) or ribavirin (800 mg/day) plus interferon alfa-2b (3 MIU TIW) for 48 weeks with a follow-up period of 6 months.
Maltese: Il-pazjenti ngħataw b'mod każwali jew Ribavirin (800 mg/jum) flimkien ma' peginterferon alfa-2b (1.5 µg/kg/ġimgħa) jew ribavirin (800 mg/jum) flimkien ma' interferon alfa-2b (3 MIU TIW) għal 48 ġimgħa b'perijodu ta' follow-up għal 6 xhur.
English: Twenty four percent of children (11/46) treated for 24 weeks and 40 % of children (19/48) treated for 48 weeks had a > 15 percentile height for age decrease from pre-treatment to the end of 5 year long term follow up compared to pre-treatment baseline percentiles.
Maltese: Erbgħa u għoxrin fil-mija tat-tfal (11/46) ikkurati għal 24 ġimgħa u 40% tat-tfal (19/48) ikkurati għal 48 ġimgħa kellhom tnaqqis ta' > 15-il perċentwali fit-tul għall-età minn qabel il-kura sal-aħħar tas-segwitu fit-tul ta' 5 snin meta mqabbel mal-perċentwali fil-linja bażi ta' qabel il-kura.
English: Please refer to the corresponding SmPC of medicinal products used in combination with Ribavirin Teva Pharma B.V..
Maltese: Jekk jogħġbok irreferi għall-SmPC korrispondenti tal-prodotti mediċinali użati flimkien ma' Ribavirin Teva Pharma B.V.
English: BN
Maltese: SLU
English: HCV/HIV co-infected patients receiving peginterferon alfa-2b/ribavirin treatment and cART may be at increased risk to develop haematological abnormalities (as neutropenia, thrombocytopenia and anaemia) compared to HCV mono-infected patients.
Maltese: Pazjenti li fl-istess ħin ikunu infettati b'HCV/HIV li jkunu qed jirċievu trattament b'peginterferon alfa-2b/ribavirin u cART jistgħu jkunu f'riskju akbar li jiżviluppaw anormalitajiet ematoloġiċi (bħala neutropenja, tromboċitopenja u anemija) meta mqabbla ma' pazjenti infettati b'HCV biss.
English: However, absolute bioavailability is approximately 45 %-65 %, which appears to be due to first pass metabolism.
Maltese: Madankollu, ir-rata assoluta ta' bijodisponibilità hi madwar 45 %-65 %, li tidher li hi minħabba l-metaboliżmu tal-ewwel passaġġ.
English: Liver biopsies were obtained before and after treatment in Study 1 and were available for 210 of the 412 subjects (51 %).
Maltese: Bijopsiji tal-fwied ittieħdu qabel u wara t-trattament fi Studju 1 u kienu disponibbli għal 210 mill-412il individwu (51 %).
English: In Study 1 (see section 5.1), decrease in absolute neutrophil count levels below 500 cells/mm3 was observed in 4 % (8/194) of patients and decrease in platelets below 50,000/mm3 was observed in 4 % (8/194) of patients receiving ribavirin in combination with peginterferon alfa-2b.
Maltese: Fi Studju 1 (ara sezzjoni 5.1), tnaqqis fl-għadd assolut tan-newtrofili taħt il-500 ċellula/mm33deher f'4 % (8/194) tal-pazjenti u tnaqqis fl-għadd tal-plejtlets għal taħt 50,000/mm33
English: Mitochondrial toxicity and lactic acidosis have been reported in HIV-positive patients receiving NRTI regimen and associated-ribavirin for co-HCV infection (see section 4.4).
Maltese: Tossiċità mitokondrijali u aċidożi lattika kienu rrappurtati f'pazjenti pożittivi għall-HIV li kienu qed jirċievu kors ta' NRTI flimkien ma' ribavirin għall-infezzjoni fl-istess ħin b'HCV (ara sezzjoni 4.4).
English: Contents of the pack and other information What Ribavirin Teva Pharma B.V. contains
Maltese: Kontenut tal-pakkett u informazzjoni oħra X'fih Ribavirin Teva Pharma B.V.
English: In combination with peginterferon alfa-2b
Maltese: Flimkien ma' peginterferon alfa-2b
English: Pigmentation disorder, dermatitis atopic, skin exfoliation
Maltese: Disturbi fil-pigmetazzjoni, dermatite atopika, qxur tal-ġilda
English: Furthermore, suicidal ideation or attempts were reported more frequently compared to adult patients (2.4 % vs 1 %) during treatment and during the 6 month follow-up after treatment.
Maltese: Barra minn hekk, ħsibijiet jew tentattivi ta' suwiċidju kienu rapportati b'mod aktar ta' spiss meta mqabbla mal-popolazzjoni adulta (2.4 % vs 1 %) waqt it-trattament u fis-6 xhur wara t-trattament.
English: Eleven percent of children (5/46) treated for 24 weeks and 13 % of children (6/48) treated for 48 weeks were observed to have a decrease from pre-treatment baseline > 30 height for age percentiles to the end of the 5 year long term follow-up.
Maltese: Ħdax fil-mija tat-tfal (5/46) ikkurati għal 24 ġimgħa u 13% tat-tfal (6/48) ikkurati għal 48 ġimgħa kien osservat li kellhom tnaqqis ta' > 30 perċentwali tat-tul għall-età mil-linja bażi ta' qabel il-kura sal-aħħar tas-segwitu fit-tul ta' 5 snin.
English: Specific pharmacokinetic evaluations for elderly subjects have not been performed.
Maltese: Ma sarux evalwazzjonijiet farmakokinetiċi speċifiċi f'pazjenti anzjani.
English: Any potential for interactions may persist for up to two months (five half-lives for ribavirin) after cessation of ribavirin therapy due to the long half-life (see section 5.2).
Maltese: Kull possibilità ta' interazzjoni tista' tippersisti sa xaharejn (ħames half-lives għal ribavirin) wara l-waqfien tat-terapija b'ribavirin minħabba l-half-life twil (ara sezzjoni 5.2).
English: Arthritis, back pain, muscle spasms, pain in extremity
Maltese: Artrite, uġigħ tad-dahar, spażmi muskolari, uġigħ flestremitajiet
English: How to store Ribavirin Teva Pharma B.V.
Maltese: Kif taħżen Ribavirin Teva Pharma B.V.
English: SVR after treatment of chronic HCV with non-pegylated interferon alfa-2b with ribavirin results in long-term clearance of the virus providing resolution of the hepatic infection and clinical 'cure' from chronic HCV.
Maltese: Ir-rispons viroloġiku sostnut wara kura għal HCV kroniku b'interferon alfa-2b mhux pegilat ma' ribavirin irriżulta fi tneħħija fuq perijodu ta' żmin twil tal-virus li jipprovdi riżoluzzjoni tal-infezzjoni epatika u ‘kura' klinika minn HCV kroniku.
English: Based on published data, single-dose ribavirin pharmacokinetics was altered (increased AUCtf and Cmax) in patients with renal dysfunction compared with control subjects (creatinine clearance > 90 mL/minute).
Maltese: Abbażi ta' dejta ippublikata, il-farmakokinetika ta' doża waħda ta' ribavirin kienet mibdula (żieda flAUCtf u Cmax) fpazjenti b'funzjoni ħażina tal-kliewi meta mqabbla ma-individwi bħala kontrolli (tneħħija ta' kreatinina > 90 mL/minuta).
English: Suicidal ideation, aggression, confusion, affect liability, behaviour disorder, agitation, somnambulism, anxiety, mood altered, restlessness, nervousness, sleep disorder, abnormal dreaming, apathy
Maltese: Ħsibijiet suwiċidali, aggressjoni, konfużjoni, jaffettwa llijabilità, disturbi ta' mġieba, agitazzjoni, ħmar il-lejl, ansjetà, burdata mibdula, irrikwitezza, nervożità, disturbi flirqad, ħolm mhux normali, apatija
English: Hyperglycaemia, hyperuricaemia, hypocalcaemia, dehydration, increased appetite
Maltese: Ipergliċemija, iperurikemija, ipokalċemija, diżidrazzjoni, żieda fl-aptit.